Saba Capital Management, L.P. Sells 29,102 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Posted by Tech Dows on Apr 6th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 29,102 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $12.28, for a total value of $357,372.56. Following the sale, the insider now directly owns 3,141,682 shares in the company, valued at approximately $38,579,854.96. The trade was a 0.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total transaction of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total value of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total value of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total value of $164,836.88.

Abrdn Life Sciences Investors Trading Down 6.0 %

Shares of HQL stock opened at $11.43 on Friday. Abrdn Life Sciences Investors has a 1-year low of $11.41 and a 1-year high of $15.90. The firm’s 50-day simple moving average is $13.42 and its 200-day simple moving average is $14.02.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, February 21st were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 16.45%. The ex-dividend date was Friday, February 21st.

Institutional Trading of Abrdn Life Sciences Investors

Institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC raised its position in shares of Abrdn Life Sciences Investors by 11.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after buying an additional 1,355 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of Abrdn Life Sciences Investors by 7.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock worth $1,199,000 after purchasing an additional 6,200 shares during the period. Kingswood Wealth Advisors LLC acquired a new position in shares of Abrdn Life Sciences Investors in the 4th quarter valued at about $160,000. Absolute Investment Advisers LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the 4th quarter worth about $5,242,000. Finally, Wolverine Asset Management LLC acquired a new stake in Abrdn Life Sciences Investors during the 4th quarter worth approximately $1,594,000. 32.21% of the stock is owned by hedge funds and other institutional investors.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.